Published in Mol Cancer Ther on June 29, 2010
A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. Blood (2010) 1.82
Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. PLoS One (2010) 1.78
Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J Clin Oncol (2011) 1.52
A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study. BMC Cancer (2016) 1.42
Squamous Cell Carcinoma - Similarities and Differences among Anatomical Sites. Am J Cancer Res (2011) 1.13
Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models. J Exp Clin Cancer Res (2014) 1.12
Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis. Clin Cancer Res (2012) 1.01
The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth. Mol Cancer Ther (2013) 0.99
Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer. J Thorac Oncol (2013) 0.91
Stimulus-dependent differences in signalling regulate epithelial-mesenchymal plasticity and change the effects of drugs in breast cancer cell lines. Cell Commun Signal (2015) 0.88
Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. Br J Cancer (2012) 0.88
Enhancing therapeutic efficacy of the MEK inhibitor, MEK162, by blocking autophagy or inhibiting PI3K/Akt signaling in human lung cancer cells. Cancer Lett (2015) 0.85
KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach. Transl Lung Cancer Res (2013) 0.84
Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer. Ann Oncol (2016) 0.82
Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation. Neoplasia (2014) 0.82
Synthetic lethal interactions for the development of cancer therapeutics: biological and methodological advancements. Hum Genet (2010) 0.82
Targeting MEK for the treatment of non-small-cell lung cancer. J Thorac Oncol (2012) 0.82
Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab. PLoS One (2013) 0.79
Targeting metabolic peculiarities: a potentially novel therapeutic approach for KRAS-mutant lung cancer? J Thorac Dis (2016) 0.75
BRCA1-deficient breast cancer cell lines are resistant to MEK inhibitors and show distinct sensitivities to 6-thioguanine. Sci Rep (2016) 0.75
Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib. Oncotarget (2016) 0.75
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 42.90
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell (2004) 19.51
BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med (2008) 14.47
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med (2005) 13.40
Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov (2009) 10.59
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta (2006) 7.33
Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol (2004) 6.61
Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res (2007) 5.59
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res (2007) 4.45
Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat (2007) 3.83
Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res (2010) 3.54
PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res (2009) 3.21
Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res (2009) 3.14
Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res (2008) 2.76
Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res (2008) 2.71
Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res (2008) 2.48
Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol (2005) 2.32
CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin Oncol (2003) 2.07
BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. Cancer Res (2008) 2.03
The methionine sulfoxide reductases: Catalysis and substrate specificities. Arch Biochem Biophys (2008) 1.85
Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene (1991) 1.79
Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases. Cancer Res (2006) 1.56
Integrative genomic analysis of phosphatidylinositol 3'-kinase family identifies PIK3R3 as a potential therapeutic target in epithelial ovarian cancer. Clin Cancer Res (2007) 1.48
Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. Int J Cancer (2009) 1.44
ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res (1991) 1.36
A novel family of transmembrane proteins interacting with beta subunits of the Na,K-ATPase. Hum Mol Genet (2007) 0.93
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol (2002) 13.81
DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell (2006) 9.47
Follicular lymphoma international prognostic index. Blood (2004) 7.20
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res (2006) 7.18
Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol (2009) 5.66
Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med (2015) 5.44
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res (2009) 5.20
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol (2012) 5.16
Salivary transcriptome diagnostics for oral cancer detection. Clin Cancer Res (2004) 4.15
CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood (2004) 4.05
Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res (2009) 3.86
Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat (2007) 3.83
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol (2013) 3.71
Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol (2003) 3.62
Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res (2010) 3.54
Imprinting on distal chromosome 7 in the placenta involves repressive histone methylation independent of DNA methylation. Nat Genet (2004) 3.47
Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol (2008) 3.35
Propionibacterium acnes strain populations in the human skin microbiome associated with acne. J Invest Dermatol (2013) 3.32
Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res (2003) 3.30
Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst (2004) 3.24
Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst (2003) 3.09
Salivary proteomic and genomic biomarkers for primary Sjögren's syndrome. Arthritis Rheum (2007) 2.90
Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res (2005) 2.85
Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res (2004) 2.81
Salivary proteomics for oral cancer biomarker discovery. Clin Cancer Res (2008) 2.81
Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther (2010) 2.78
The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res (2004) 2.72
Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol (2002) 2.67
Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst (2007) 2.65
p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell (2003) 2.65
Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell (2011) 2.56
Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging (2010) 2.48
Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol (2010) 2.48
Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol (2004) 2.46
Tazarotene-induced gene 1 (TIG1) expression in prostate carcinomas and its relationship to tumorigenicity. J Natl Cancer Inst (2002) 2.41
Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer. Gut (2011) 2.38
Prognostic impact of micrometastases in colon cancer: interim results of a prospective multicenter trial. Ann Surg (2007) 2.28
β-cell mass and turnover in humans: effects of obesity and aging. Diabetes Care (2012) 2.20
iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet (2006) 2.20
Conservation of the H19 noncoding RNA and H19-IGF2 imprinting mechanism in therians. Nat Genet (2008) 2.20
The prolyl isomerase Pin1 orchestrates p53 acetylation and dissociation from the apoptosis inhibitor iASPP. Nat Struct Mol Biol (2007) 2.13
Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer. Gastroenterology (2009) 2.13
Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer (2005) 2.12
A general relationship between disorder, aggregation and charge transport in conjugated polymers. Nat Mater (2013) 2.11
Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst (2004) 2.06
Electron-pinned defect-dipoles for high-performance colossal permittivity materials. Nat Mater (2013) 2.05
Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer. Clin Cancer Res (2011) 2.02
Growth inhibitory effect of low fat diet on prostate cancer cells: results of a prospective, randomized dietary intervention trial in men with prostate cancer. J Urol (2010) 1.94
Vestibular loss causes hippocampal atrophy and impaired spatial memory in humans. Brain (2005) 1.92
Adaptation of nutrient supply to fetal demand in the mouse involves interaction between the Igf2 gene and placental transporter systems. Proc Natl Acad Sci U S A (2005) 1.90
Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res (2011) 1.89
Ten years of dengue drug discovery: progress and prospects. Antiviral Res (2013) 1.84
Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol (2005) 1.83
Fluorescence lifetime imaging system for in vivo studies. Mol Imaging (2007) 1.83
Lung cancer chemoprevention with celecoxib in former smokers. Cancer Prev Res (Phila) (2011) 1.77
FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer. Cancer Res (2010) 1.73
Information chaos in primary care: implications for physician performance and patient safety. J Am Board Fam Med (2011) 1.72
Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS One (2012) 1.70
Interaction between a G-patch protein and a spliceosomal DEXD/H-box ATPase that is critical for splicing. Mol Cell Biol (2004) 1.70
Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. Arthritis Rheum (2011) 1.68
Serum circulating human mRNA profiling and its utility for oral cancer detection. J Clin Oncol (2006) 1.67
Electrochemical sensor for multiplex biomarkers detection. Clin Cancer Res (2009) 1.67
The prognostic effect of micrometastases in previously staged lymph node negative (N0) colorectal carcinoma: a meta-analysis. Ann Surg Oncol (2006) 1.66
EMAGE--Edinburgh Mouse Atlas of Gene Expression: 2008 update. Nucleic Acids Res (2007) 1.66
Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene (2004) 1.64
HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. Clin Cancer Res (2008) 1.63
Should a positive surgical margin following radical prostatectomy be pathological stage T2 or T3? Results from the SEARCH database. J Urol (2003) 1.63
Structural basis for nick recognition by a minimal pluripotent DNA ligase. Nat Struct Mol Biol (2007) 1.63
Left ventricular strain patterns in dilated cardiomyopathy predict response to cardiac resynchronization therapy: timing is not everything. J Am Soc Echocardiogr (2009) 1.61
Reduction of the efficacy of methotrexate by the use of folic acid: post hoc analysis from two randomized controlled studies. Arthritis Rheum (2005) 1.61
Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol (2006) 1.60
SRC: a century of science brought to the clinic. Neoplasia (2010) 1.58
Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign. Cancer (2010) 1.56
Organic thin-film electronics from vitreous solution-processed rubrene hypereutectics. Nat Mater (2005) 1.53
Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. J Clin Oncol (2004) 1.50
Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. Clin Cancer Res (2006) 1.50
Complications following prostate needle biopsy requiring hospital admission or emergency department visits - experience from 1000 consecutive cases. BJU Int (2012) 1.48
Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. Neoplasia (2010) 1.48
Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget (2014) 1.47
Randomized clinical trial of brewed green and black tea in men with prostate cancer prior to prostatectomy. Prostate (2014) 1.47
FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin Cancer Res (2009) 1.47